1) New clinical study "Potential of Moderate Whole Body
Hyperthermia to Enhance Response (POWER)" at Charite University Berlin
A total of six different patient groups are
included in the randomized phase II study, all with palliative therapy
intentions (defined subgroups of patients with metastatic malignant melanoma,
pancreatic ca, breast ca, sarcoma, head&neck ca, prostate ca).
Primary outcome measure is the change in
the number of circulating tumor cells before therapy vs after therapy.
Secondary outcome measures are among others tumor response, quality of life
including depressions and fatigue, various biomarkers relevant for immune
response and tumor microenvironment, survival and progression-free survival
rate.
Responsibility for the study: PD Dr. med.
Sebastian Zschaeck from Department of Radiation Oncology and Radiotherapy.
Get more detailed information in the
clinical trial registry: https://clinicaltrials.gov/ct2/show/NCT05821166
Contacts for referring patients:
Sebastian Zschaeck, MD; +49-30-450650764,
sebastian.zschaeck@charite.de
Julian Weingaertner, MD; +49-30-450657057, julian.weingaertner@charite.de
2) Publication on the relationship between cytokines measured
in plasma and the antidepressant effect after mild-moderate whole-body
hyperthermia
New publication on the relationship between
plasma cytokines and antidepressant response after mild-moderate whole-body
hyperthermia:
Flux MC et al: Association of plasma
cytokines and antidepressant response following mild-intensity whole-body
hyperthermia in major depressive disorder. Transl Psychiatry. 2023 Apr
21;13(1):132;
open access https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10121589/
In 2016, Janssen et al. in JAMA Psychiatry
reported a randomized clinical trial (RCT) on the antidepressant effect of a
single mild-moderate whole-body hyperthermia (GHT) treatment in drug-naïve
patients, which showed a strong and unexpectedly long-lasting effect.
https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2521478.
The blood samples from this study have now
been evaluated retrospectively. The hypothesis of a decrease in IL-6 could not
be confirmed, on the contrary, an increase in IL-6 was the only significant
effect of GHT on cytokine levels. Interestingly, this increase correlated
positively with the antidepressant effect. This unexpected finding and the
pleiotropic properties of IL-6 are discussed extensively in the Discussion
section.
The RCT, published in JAMA Psychiatry 2016,
was a groundbreaking pilot that has generated significant interest in the
topic. However, there were some significant limitations, in particular the
small number of participants of 15 vs. 14 patients.
The study motivated other academic
institutions to carry out similar study protocols (KEM Essen: HYPE1 and HYPE2,
Charite Berlin: GKH-D). These studies were severely delayed due to the Corona
crisis, but the studies in Essen are almost complete. Numerous biomarkers were
also recorded in these, which enable a comparison with the data that has now
been published.
3) Award for a Portuguese publication on the use of
whole-body hyperthermia to reduce traumatic and depressive symptoms in accident
victims
The
publication appeared in Portuguese in 2022.
Queirós
C, Oliveira S, Fonseca SM, Faria S, Cunha S: HIPERTERMIA NA REDUÇÃO DE SINTOMAS
TRAUMÁTICOS E DEPRESSIVOS EM PROFISSIONAIS ENVOLVIDOS EM ACIDENTES. territory
29 (II), 2022, 53-66. OPEN ACCESS:
https://impactum-journals.uc.pt/territorium/article/view/9296/8884, English
abstract.
In
a pilot study, moderate whole-body hyperthermia led to a reduction in traumatic
and depressive symptoms - in particular sleep disorders - in professionals
involved in accidents (e.g. train drivers after suicides on the rails).
The
psychologist Prof. Cristina Queiros (Faculdade de Psicologia e de Ciências da
Educação da Universidade do Porto) has now received the renowned
"Science2022" prize for this publication, which was presented at the
VI Congresso Internacional de Riscos (Faculdade de Letras da Universidade de
Coimbra, 23-26 May 2023): https://noticias.up.pt/professora-e-investigadora-da-fpceup-vence-premio-premio-ciencia-2022/
4) DEGRO 2023 – 22.-24. June in Kassel: Presentation of the
thermography-controlled wIRA surface hyperthermia
At the 29th Congress of the German Society
for Radiation Oncology (DEGRO) from 22.-24. June in Kassel, heckel will be
presenting the thermography-controlled wIRA surface hyperthermia
(hydrosun®TWH1500) at booth K1 (next to the poster area). We are looking
forward to your visit!
5) Sep 26, 2023 - September 29, 2023: Two
overlapping congresses with heckel participation - ESHO Annual Meeting in
Cologne and WOCOIO Integrative Oncology Congress in Stuttgart/Ludwigsburg
From Sep 26, 2023 - Sep 29, 2023, two
interesting congresses will unfortunately overlap:
• 35th ESHO Meeting (European Society for
Hyperthermic Oncology) in Cologne,
https://esho-congress.eu/
• WOCOIO - WORLD CONGRESS OF INTEGRATIVE
ONCOLOGY in Stuttgart / Ludwigsburg, organized by ESIO - European Society for
Integrative Oncology e.V.,
https://wocoio.com/
heckel is a sponsor at both congresses and
is represented with a stand.
※본 게시물은 독일 heckel gmbH.에서 발행한 뉴스레터를 전달받아 발행한 것입니다.
